Angiotech Pharmaceuticals (ANPI) Announces FDA 510(k) Clearance of Option Inferior Vena Cava Filter
More News related to ANPI
- Angiotech Pharmaceuticals, Inc. announces financial results for the third quarter ended September 30, 2009
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Angiotech Pharmaceuticals announces commercial launch of the Tan Endoglide(TM) Endothelium Insertion System in the United States at the American Academy of Ophthalmology annual meeting
- Angiotech Pharmaceuticals (ANPI) Receives FDA Letter Regarding 510k Submission of Bio-Seal
- Angiotech Pharmaceuticals provides update on Bio-Seal(TM) 510(K) submission
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, for use in both permanent and retrievable indications.
The Option IVC Filter is used for the prevention of recurrent pulmonary embolism (PE). The device is implanted, typically by interventional radiologists in a minimally invasive procedure, into the body's inferior vena cava to prevent PE. Option is specifically designed for use as both a permanent or temporary implant (in temporary, or retrievable, indications, a physician may later perform a second surgical procedure to remove the Option IVC Filter if necessary or where mandated clinically).
More from Release
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
